↓ Skip to main content

Dove Medical Press

Article Metrics

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, August 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
44 Mendeley
Title
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, August 2018
DOI 10.2147/copd.s169958
Pubmed ID
Authors

Roland Buhl, Carl-Peter Criée, Peter Kardos, Claus Vogelmeier, Konstantinos Kostikas, Nadine S Lossi, Heinrich Worth

Abstract

No observational studies have evaluated the "real-world" effectiveness of dual bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β2-agonist plus long-acting muscarinic antagonist plus inhaled corticosteroid) in COPD. DACCORD is a non-interventional, observational clinical study that recruited patients following COPD maintenance therapy initiation or change in maintenance therapy between or within therapeutic class. Given the non-interventional nature of the study, the decision to initiate or change medication had to be made by the patients' physicians prior to inclusion in DACCORD. We used a matched-pairs analysis to compare disease progression in two patient groups: those receiving dual bronchodilation vs those receiving triple therapy (each group n=1,046). In two subgroups of patients matched according to a broad range of demographic and disease characteristics, over 1 year, fewer patients receiving dual bronchodilation exacerbated than those receiving triple therapy (15.5% vs 26.6%; P<0.001), with a greater improvement from baseline in COPD Assessment Test total score at 1 year (mean±SD -2.9±5.8 vs -1.4±5.5;P<0.001). When analyzed according to prior therapy, the highest rate of exacerbations was in patients on triple therapy prior to the study who remained on triple therapy. Those changing from mono-bronchodilator to dual bronchodilation had the greatest COPD Assessment Test total score improvement. In this "real-life" cohort of patients with COPD, most of whom had not exacerbated in the 6 months prior to entry, triple therapy did not seem to improve outcomes compared with dual bronchodilation in terms of either exacerbations or health status. Our analyses clearly demonstrate the potential impact of prior medication on study results, something that should be taken into account when interpreting the results even of controlled clinical trials.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 11%
Other 5 11%
Student > Bachelor 5 11%
Researcher 4 9%
Student > Ph. D. Student 4 9%
Other 7 16%
Unknown 14 32%
Readers by discipline Count As %
Medicine and Dentistry 15 34%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Economics, Econometrics and Finance 4 9%
Biochemistry, Genetics and Molecular Biology 2 5%
Psychology 1 2%
Other 3 7%
Unknown 14 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2018.
All research outputs
#8,039,007
of 13,477,526 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#985
of 1,642 outputs
Outputs of similar age
#147,396
of 267,701 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#29
of 48 outputs
Altmetric has tracked 13,477,526 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,642 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,701 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.